• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why ORIC Pharmaceuticals (ORIC) Is Back In The Spotlight

    Simply Wall St·09/17/2026 11:24:49
    语音播报

    ORIC Pharmaceuticals (ORIC) kicked off its Himalayas-1 global Phase 3 trial of rinzimetostat in prostate cancer, pairing the drug with Bayer’s darolutamide and backing the effort with funding expected to last into 2028.

    For ORIC Pharmaceuticals, investors have seen a sharp 47.7% 90 day share price return and a 53.49% year to date share price gain. The 1 year total shareholder return of 19.2% and 3 year total shareholder return of 56.75% point to momentum that has been building around its clinical progress and funding runway.

    See how ORIC Pharmaceuticals compares with other high momentum biotech opportunities in the hand picked 16 high quality undiscovered gems that remain under many investors’ radar.

    After a surge like ORIC Pharmaceuticals has just logged, investors tend to ask the same thing in different ways. Has the Himalayas-1 launch simply caught the stock up to its promise, or does the current valuation still leave meaningful upside on the table?

    Preferred Price-to-Book Multiple of 3.4x: Is it justified?

    On simple numbers, ORIC Pharmaceuticals trades on a P/B of 3.4x, which puts a clear valuation line in the sand for a pre-revenue biotech with a $12.54 share price.

    P/B matters here because ORIC Pharmaceuticals has no revenue and is loss making, so investors lean on the balance sheet and pipeline expectations rather than earnings based ratios like P/E.

    Against its own peer set, the picture is mixed. ORIC is flagged as good value versus a peer average P/B of 5.5x, yet it screens as expensive relative to the wider US Biotechs industry on 2.2x. This suggests the market is assigning a richer multiple than the sector overall while still keeping a discount to more direct comparables.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 3.4x (ABOUT RIGHT)

    Still, the ORIC Pharmaceuticals story carries clear pressure points, including trial setbacks for rinzimetostat or enozertinib, as well as the ongoing losses tied to a US$140.351 million net income shortfall.

    Find out about the key risks to this ORIC Pharmaceuticals narrative.

    Next Steps

    If the tone so far feels cautiously optimistic, now is the time to check the underlying data yourself and decide whether ORIC Pharmaceuticals fits your risk tolerance. To pressure test that view against flagged issues, start with the 4 important warning signs.

    Looking for more investment ideas beyond ORIC Pharmaceuticals?

    If ORIC Pharmaceuticals has caught your attention, do not stop there. Broaden your watchlist with other focused ideas that match your risk profile and style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.